Interobserver reproducibility of diffusion-weighted MRI in monitoring tumor response to neoadjuvant therapy in esophageal cancer

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Kwee, Robert M ^a,b   Dik, Alexander K ^a   Sosef, Meindert N ^a,c   Berendsen, Ralph C M ^a   Sassen, Sander ^a   Lammering, Guido ^d   Clarijs, Ruud ^a   Oostenbrug, Liekele E ^a   Blom, Rachel L G M ^e   Vliegen, Roy F A ^a  

^a Sittard Geleen Heerlen   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Surgical Collaborative Network Limburg   (Netherlands)

^d MediClin Robert Janker Clinic   (Germany)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; DISTANT METASTASIS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MALE; REPRODUCIBILITY; TREATMENT RESPONSE; TUMOR VOLUME; VOLUMETRY; ADENOCARCINOMA; ADJUVANT THERAPY; CHEMORADIOTHERAPY; CLINICAL TRIAL; ESOPHAGEAL NEOPLASMS; MIDDLE AGED; OBSERVER VARIATION; PHYSIOLOGIC MONITORING; PROCEDURES; PROGNOSIS; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; CHEMORADIOTHERAPY; DIFFUSION MAGNETIC RESONANCE IMAGING; ESOPHAGEAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEOADJUVANT THERAPY; OBSERVER VARIATION; PROGNOSIS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 84899440477     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092211     Document Type: Article

References (20)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2008) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917.
2. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, et al. (2011) Australasian Gastro-Intestinal Trials Group. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 12:681-692.
3. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, et al; CROSS Group (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074-2084.
4. Malthaner RA, Collin S, Fenlon D (2006) Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev 3:CD001556.
5. Kwee RM (2010) Prediction of tumor response to neoadjuvant therapy in patients with esophageal cancer with use of 18F FDG PET: a systematic review. Radiology 254:707-717.
6. MRIsafety.com. Available: http://www.mrisafety.com. Accessed 2013 Oct 5.
7. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair Mr, et al. (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9:676-682.
8. Sakurada A, Takahara T, Kwee TC, Yamashita T, Nasu S, et al. (2009) Diagnostic performance of diffusion-weighted magnetic resonance imaging in esophageal cancer. Eur Radiol 19:1461-1469.
9. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, et al. (1994) Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 73:2680-2686. (Pubitemid 24166250)
10. Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1:307-310. (Pubitemid 16134762)
11. Thoeny HC, Ross BD (2010) Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging; 32:2-16.
12. Aoyagi T, Shuto K, Okazumi S, Shimada H, Nabeya Y, et al. (2010) Evaluation of the clinical staging of esophageal cancer by using diffusion-weighted imaging. Exp Ther Med 1:847-852.
13. Aoyagi T, Shuto K, Okazumi S, Hayano K, Satoh A, et al. (2012) Apparent diffusion coefficient correlation with oesophageal tumour stroma and angiogenesis. Eur Radiol 22:1172-1177.
14. Aoyagi T, Shuto K, Okazumi S, Shimada H, Kazama T, et al. (2011) Apparent diffusion coefficient values measured by diffusion-weighted imaging predict chemoradiotherapeutic effect for advanced esophageal cancer. Dig Surg 28:252-257.
15. Sun YS, Cui Y, Tang L, Qi LP, Wang N, et al. (2011) Early evaluation of cancer response by a new functional biomarker: apparent diffusion coefficient. AJR Am J Roentgenol 197:W23-29.
16. Lambregts DM, Beets GL, Maas M, Curvo-Semedo L, Kessels AG, et al. (2011) Tumour ADC measurements in rectal cancer: effect of ROI methods on ADC values and interobserver variability. Eur Radiol 21:2567-2574.
17. Enzinger PC, Mayer RJ (2003) Esophageal cancer. N Engl J Med 349:2241-2252. (Pubitemid 37485141)
18. Ancona E, Ruol A, Santi S, Merigliano S, Sileni VC, et al. (2001) Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 91:2165-2174. (Pubitemid 32476382)
19. Donington JS, Miller DL, Allen MS, Deschamps C, Nichols FC 3rd, et al. (2003) Tumor response to induction chemoradiation: influence on survival after esophagectomy. Eur J Cardiothorac Surg 24:631-636.
20. Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, et al. (2005) Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 103:1347-1355. (Pubitemid 40410728)